Co-Diagnostics

Co-Diagnostics, Inc. engages in the development and innovation of molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications. Its diagnostics systems enable very rapid, low-cost, molecular testing for organisms and genetic diseases by automating historically complex procedures in both the development and administration of tests. The company was founded by Brent C. Satterfield and Dwight Howard Egan on April 18, 2013 and is headquartered in Salt Lake City, UT.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Co-Diagnostics reports Q1 results, focuses on growth and innovation

Co-Diagnostics reported mixed financial results for Q1 2024, with revenue decrease but gross profit increase.
The company is strategically focused on commercialization efforts, product development, and managing expenses for growth.
Despite facing challenges such as net losses and operational complexities, Co-Diagnostics remains optimistic about future opportunities.
With a strong cash position and ongoing FDA submissions, Co-Diagnostics is poised for potential revenue growth and market expansion.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SALT LAKE CITY, July 22, 2021  /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it has added to its suite of intellectual property protection after being awarded a patent from the Republic of Korea's Intellectual Property Office for the Company's CoPrimer™ technology. Developed in 2013, Co-Diagnostics' solely-owned CoPrimer technology received its first patent from the United States Patent Office in 2018, and underpins the Company's molecular diagnostic test products that have been deployed in laboratories and hospitals in over 50 countries and across the United States.

Co-Diagnostics, Inc. Strengthens Intellectual Property Portfolio with New International CoPrimer™ Patent

The stock price of Co-Diagnostics Inc (NASDAQ: CODX) increased by 9.67% yesterday. This is why it happened.

CODX Stock Increased 9.67%: Why It Happened

CoDiagnostics, Inc. (CODX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Strength Seen in CoDiagnostics, Inc. (CODX): Can Its 9.7% Jump Turn into More Strength?

BioNTech SE

Moderna

Novavax

Pfizer

Vaxart

The surge in cases and deaths could significantly ramp up demand for these companies' existing and pipeline products.

Why Coronavirus Stocks Are Zooming Higher Today

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Are Investors Undervaluing CoDiagnostics, Inc. (CODX) Right Now?

Co-Diagnostics, Inc. (NASDAQ:CODX) has announced that its Logix Smart SARS-CoV-2 DS (Direct Saliva) test has obtained regulatory authorization to be sold as an in vitro diagnostic (IVD) for the diagnosis of coronavirus (COVID-19) in markets that accept CE markings. The company noted that the test is available now for purchase from its Utah-based ISO-13485:2016 certified facility.

Co-Diagnostics, Inc. says its Logix Smart cornavirus test has obtained regulatory authorization to be sold in markets that accept CE markings

SALT LAKE CITY, June 18, 2021 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that its Logix Smart™ SARS-CoV-2 DS (Direct Saliva) has obtained regulatory authorization to be sold as an in vitro diagnostic ("IVD") for the diagnosis of COVID-19 in markets that accept CE markings, and is now available for purchase from the Company's Utah-based ISO-13485:2016 certified facility. Co-Diagnostics' Logix Smart DS test kit is designed to detect the presence of the RdRp and E genes of SARS-CoV-2 directly from minimally processed human saliva samples while eliminating RNA extraction of the samples, a costly and time-consuming process required by most PCR tests.

Co-Diagnostics, Inc Receives CE Marking for Direct Saliva SARS-CoV-2 Test

Co-Diagnostics, Inc. (NASDAQ:CODX) said it will be presenting virtually this week at the 28th International Biodetection Technologies Conference, as well as hosting a virtual booth at the 65th Annual Caribbean Public Health Agency (CARPHA) Health Research Conference. The International Biodetection Technologies Conference is being held on June 18, 2021.

Co-Diagnostics says it will be presenting virtually at two conferences virtually this week

SALT LAKE CITY, June 15, 2021 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it will be presenting virtually this week at the 28th International Biodetection Technologies Conference as well as hosting a virtual booth at the 65th Annual CARPHA Health Research Conference. The Biodetection Technologies Conference, an internationally recognized meeting for experts in detection and identification of biological threats held on June 18, will focus on point-of-care diagnostics for improving global health and biodefence.

Co-Diagnostics, Inc. to Present at Upcoming Technology and Health Research Conferences

Vaccine hesitancy and new coronavirus variants are a threat to herd immunity. The alternative solution to vaccination for re-opening the economy is mass testing.

Co-Diagnostics: No One-Hit Wonder

Coinbase

Dillard's

Disney

Plantronics

Some of the stocks that may grab investor focus today are: Walt Disney Co (NYSE: DIS) reported upbeat earnings for its second quarter, while sales missed expectations. Disney+ ended the second quarter with 103.6 million subscribers.

5 Stocks To Watch For May 14, 2021

Co-Diagnostics, Inc. (CODX) CEO Dwight Egan on Q1 2021 Results - Earnings Call Transcript

CoDiagnostics, Inc. (CODX) delivered earnings and revenue surprises of 30.00% and 2.69%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

CoDiagnostics, Inc. (CODX) Beats Q1 Earnings and Revenue Estimates

Shares of Co-Diagnostics (NASDAQ:CODX) moved higher in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share increased 620.00% year over year to $0.26, which beat the estimate of $0.22.

Recap: Co-Diagnostics Q1 Earnings

Co-Diagnostics Inc (NASDAQ:CODX) reported that it earned a first-quarter net profit -- versus a loss last year -- on strong sales of its Logix Smart COVID-19 Test. For the quarter ended March 31, the company said income before taxes was $9.9 million as it generated revenue of $20 million.

Co-Diagnostics turns 1Q net profit of nearly $8M on strong sales of its Logix Smart COVID-19 Test

CoDiagnostics, Inc. (CODX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

CoDiagnostics, Inc. (CODX) Earnings Expected to Grow: Should You Buy?

SALT LAKE CITY, May 4, 2021 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today it will release its first-quarter 2021 results on Thursday, May 13, 2021, after the market close. The Company will also host a conference call and webcast on the same day at 4:30 p.m.

Co-Diagnostics, Inc. Announces First-Quarter 2021 Earnings Release Date and Webcast

SALT LAKE CITY, April 29, 2021 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests, announced today that it will be accompanying Dr. Heather Fehling, Chief Scientific Officer at Clinical Reference Lab ("CRL") in a webinar titled "A New Generation of PCR: At-home Testing and Preparing for Emerging Strains of COVID-19" on Thursday, April 29 at 2:00 PM EDT. The 360Dx webinar is expected to provide insights regarding future applications of PCR testing for COVID-19, how CRL is able to provide non-invasive and highly accurate saliva PCR tests for at-home collection, and how new PCR science and technology is enabling and expanding the applications and accessibility of PCR tests.

Co-Diagnostics, Inc. and Partner CRL to Discuss Saliva Testing and Future Applications of PCR in 360Dx Webinar

Co-Diagnostics Inc (NASDAQ:CODX) has noted that its Indian manufacturing facility, CoSara Diagnostics Pvt Ltd, has garnered media attention for its actions to provide much-needed coronavirus (COVID-19) diagnostics as a wave of infections has led to the world's worst outbreak since the pandemic began. An article in the Times of India, as well as other media sources, have discussed the increased capacity that has resulted from CoSara's efforts to provide test kits and technical support for its government and private lab customers, Co-Diagnostics said.

Co-Diagnostics says its CoSara joint venture in India garnering media attention as it combats coronavirus surge

SALT LAKE CITY, April 28, 2021 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests, announced today that its Indian manufacturing facility, CoSara Diagnostics Pvt. Ltd. ("CoSara," or the "JV", a Joint Venture with Synbiotics Ltd) has been featured in recent press highlighting its actions to provide much-needed COVID-19 diagnostics as a wave of infections has led to the world's worst COVID-19 outbreak since the pandemic began.

Co-Diagnostics, Inc. JV CoSara Diagnostics Recognized for Work Combating COVID-19 Surge in India

BioDelivery Sciences

Kamada

Surface Oncology Inc

Viemed Healthcare

As of April 21, the GuruFocus All-in-One Screener, a Premium feature, found that the following guru-owned utilities have low price-earnings ratios. While some of them are great value investments, others may need to be researched more carefully, according to the discounted cash flow calculator.

5 Health Care Stocks Trading with Low Price-Earnings Ratios

Co-Diagnostics Inc (NASDAQ:CODX), a molecular diagnostics company with a patented platform for the development of diagnostic tests, has revealed that its Logix Smart COVID-19 Test Kit was used by Australian researchers to demonstrate rapidly deployable mobile molecular diagnostics support for remote locations, with the peer-reviewed results published in the ‘Journal of Medical Microbiology.' The Utah-based company said the study was performed using readily available open-source equipment and materials that could be successfully operated in regional clinical laboratories, many of which are not currently equipped for molecular diagnostics.

Co-Diagnostics says Logix Smart COVID-19 Test performance validated by Australian researchers in peer-reviewed publication

SALT LAKE CITY, April 20, 2021 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests, announced today that its Logix Smart™ COVID-19 Test Kit was used by Australian researchers to demonstrate rapidly deployable mobile molecular diagnostics support for remote locations, with the peer-reviewed results published in the Journal of Medical Microbiology. The test demonstrated an analytical sensitivity of 1010 viral copies/ml, comparable to others used across W.

Co-Diagnostics, Inc. Test Performance Demonstrated by Australian Researchers in Peer-Reviewed Publication

CODX stock rose on the pandemic, but its prospects moving forward look bleak with a sales strategy that is suspect at best. The post If You Rode the Co-Diagnostics Stock Pandemic Highs, It's Time to Bail appeared first on InvestorPlace.

If You Rode the Co-Diagnostics Stock Pandemic Highs, It's Time to Bail

Co-Diagnostics Inc (NASDAQ:CODX) CEO Dwight Egan told Yahoo! Finance that “we believe COVID-19 will be here till the end of time” -- and that means individuals and organizations will need quick and easy tests partnered with vaccines to return to normalcy.

News for Co-Diagnostics Stock (CODX)